Most critically, by study end, 13 of 25 patients in the active group (>50%) and only 2 in the sham group met response criteria on the HAMD. 9 patients in the active group (36%) and no patients in the sham group met criteria for clinical remission. A further 45% of patients in the sham group who crossed over to active treatment at trial end went on to respond in a manner meeting response criteria (33% remission criteria).